Page 18 - Read Online

Page 12 of 14 Gottlieb et al. J Cancer Metastasis Treat 2018;4:37 I http://dx.doi.org/10.20517/2394-4722.2018.26

Ethical approval and consent to participate
This study was approved by the ethical review board of Jewish General Hospital.

Consent for publication
Not applicable.

Copyright
© The Author(s) 2018.

REFERENCES
1. Lawrence MS, Stojanov P, Mermel CH, Robinson JT, Garraway LA, Golub TR, Myerson M, Gabriel SB, Lander ES, Getz G. Discovery
and saturation analysis of cancer genes across 21 tumor types. Nature 2014;505:495-501.
2. Martincorena I, Roshan A, Gerstung M, Van Loo P, McLaren S, Wedge DC, Fullam A, Alexandrov LB, Tubio JM, Stebbings L, Menzies
A, Widaa S, Stratton MR, Jones PH, Campbell PJ. Tumor evolution. High burden and pervasive selection of somatic mutations in normal
human skin. Science 2015;348:880-6.
3. Schaefer MH, Serrano L. Cell type-specific properties and environment shape tissue specificity of cancer genes. Sci Rep 2016;6:2707.
4. Williamson LM, Lees-Miller SP. Estrogen receptor a-mediated transcription induces cell cycle-dependent DNA double-strand breaks.
Carcinogenesis 2011;32:279-85.
5. Savage KI, Matchett KB, Barros EM, Cooper KM, Irwin GW, Gorski JJ, Orr KS, Vohhodina J, Kavanagh JN, Madden AF, Powell A, Manti
L, McDade SS, Park BH, Prise KM, McIntosh SA, Salto-Tellez M, Richard DJ, Elliott CT, Harkinet DP. BRCA1 deficiency exacerbates
estrogen-induced DNA damage and genomic instability. Cancer Res 2014;74:2773-84.
6. Kleppe M, Levine RL. Tumor heterogeneity confounds and illuminates: assessing the implications. Nat Med 2014;20:342-4.
7. Gottlieb B, Alvarado C, Wang C, Gharizadeh B, Babrzadeh F, Richards B, Basik M, Beitel LK, Trifiro M. Making sense of intra-tumor
genetic heterogeneity: altered frequency of androgen receptor CAG repeat length variants in breast cancer tissues. Hum Mutat 2013;34:610-
8.
8. Ng CK, Scultheis AM, Bidard FC, Wegelt B, Reis-Filho JS. Breast cancer genomics from microarray to massively parallel sequencing:
paradigms and new insights. J Natl Cancer Inst 2015;107:djv015.
9. Wang Y, Waters J, Leung ML, Unruh A Roh W, Shi X, Chen K, Scheet P Vattathil S, Liang H, Multani A, Zhang H, Zhao R, Michor F,
Meric-Bernstam F, Navin NE. Clonal evolution in breast cancer revealed by single nucleus genome sequencing. Nature 2014;512:155-60.
10. Raphael BJ, Dobson JR, Oesper L, Vandin F. Identifying driver mutations in sequenced cancer genomes: computational approaches to
enable precision medicine. Genome Med 2014;6:5.
11. McFarland CA, Yaglom YA, Wojtkowiak JW, Scott JG, Morse DL, Sherman MY, Mirny LA. The damaging effect of passenger mutations
on cancer progression. Cancer Res 2017;77:4763-72.
12. Fortunato A, Boddy A, Mallo D, Aktipis A, Maley CC, Pepper JW. Natural selection in cancer biology: from molecular snowflakes to trait
hallmarks. Cold Spring Harb Perspect Med 2017;7:a029652.
13. Schirmer M, Ijaz UZ, D’Amore R, Hall N, Sloan WT, Quince C. Insight into biases and sequencing errors for amplicon sequencing with the
Illumina MiSeq platform. Nucleic Acids Res 2015;43:e37.
14. Forsberg LA, Gisselsson D, Damanski JP. Mosaicism in health and disease - clones picking up speed. Nat Rev Genet 2017;18:128-42.
15. Hoang ML, Kinde I, Tomasetti C, Wyatt McMahon K, Rosenquist TA, Grollman AP, Kinzler KW, Vogelstein B, Papadopoulos N. Genome-
wide quantification of rare somatic mutations in normal human tissues using massively parallel sequencing. PNAS 2016;113:9846-51.
16. Anglesio MS, Papadopoulos N, Ayhan A, Nazeran TM, Noë M, Horlings HM, Lum A, Jones S, Senz J, Seckin T, Ho J, Wu RC, Lac V,
Ogawa H, Tessier-Cloutier B, Alhassan R, Wang A, Wang Y, Cohen JD, Wong F, Hasanovic A, Orr N, Zhang M, Popoli M, McMahon W,
Wood LD, Mattox A, Allaire C, Segars J, Williams C, Tomasetti C, Boyd N, Kinzler KW, Gilks CB, Diaz L, Wang TL, Vogelstein B, Yong
PJ, Huntsman DG, Shih IM. Cancer-associated mutations in endometriosis without cancer. N Engl J Med 2017;376:1835-48.
17. Guedj M, Marisa I, de Renies A, Orsetti B, Schiappa R, Bibeau F, MacGrogan G, Lerebours F, Finetti P, Longy M, Bertheau P, Bertrand F,
Bonnet F, Martin AL, Feugeas JP, Bièche I, Lehmann-Che J, Lidereau R, Birnbaum D, Bertucci F, de Thé H, Theillet C. A refined molecular
taxonomy of breast cancer. Oncogene 2012;31:1196-206.
18. Lehnann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, Pietenpol JA. Identification of human triple-negative breast cancer
subtypes and preclinical models for selection of targeted therapies. J Clin Invest 2011;121:2750-67.
19. Hirschfield KM, Ganesan S. Triple-negative breast cancer: molecular subtypes and targested therapy. Curr Opin Obstet Gyncol 2014;26:34-
40.
20. Collins LC, Cole KS, Marotti JD, Hu R, Schnitt SJ, Tamimi RM. Androgen expression in breast cancer in relation to molecular phenotype:
results from the Nurses Health Study. Mod Pathol 2011;24:924-31.
21. Fujii R, Hanamura T, Sizuki T, Gohno T, Shibahara Y, Niwa T, Yamaguchi Y, Ohnuki K, Kakugawa Y, Hirakawa H, Ishida T, Sasano H,
Ohuchi N, Hayashi S. Increased androgen receptor activity and cell proliferation in aromatase inhibitor-resistant breast carcinoma. J Steroid
Biochem Mol Biol 2014;144:513-22.
22. Peters KM, Edwards SL, Nair SS, French JD, Bailry PJ, Salkield K, Stein S, Wagner S, Francis GD, Clark SJ, Brown MA. Androgen
receptor expression predicts cancer survival: the role of genetic and epigenetic events. BMC Cancer 2012;12:132.
23. MacNamara KM, Moore NL, Hickey TE, Sasano H, Tiley WD. Complexities of androgen receptor signaling in breast cancer. Endocr Relat